Aduro to Host and Webcast an Investor Event to Review Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) A...
November 06 2018 - 4:16PM
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that the company
will host and webcast an investor event on Friday, November 9, 2018
at 6:30 p.m. Eastern Time in Washington, D.C. The event will
feature special guest speaker Jason J. Luke, M.D., FACP, Assistant
Professor of Medicine at the University of Chicago and a principal
investigator for the Phase 1 dose-finding studies of ADU-S100
(MIW815), a novel STING (stimulator of interferon genes) pathway
activator. ADU-S100 is currently being evaluated as a single agent
and in combination with spartalizumab (PDR001), an investigational
anti-PD-1 compound in patients with advanced/metastatic solid
tumors or lymphomas.
To access the live webcast and subsequent archived recording of
this and other company presentations, please visit the investor
section of Aduro's website at www.aduro.com. The archived webcast
will remain available for replay on Aduro’s website for 30
days.
Aduro’s posters will be on display on Friday, November 9, 2018
from 8 a.m. – 8 p.m. ET and Saturday, November 10, 2018 from 8 a.m.
– 8:30 p.m. ET in Hall E. at the Walter E. Washington Convention
Center. Details of Aduro’s posters and oral presentations are as
follows:
P309 |
Phase I
dose-finding study of MIW815 (ADU-S100), an
intratumoral |
|
STING agonist,
in patients with advanced solid tumors or lymphomas |
Session: |
Rapid Oral Abstract
Presentation Session |
Date: |
Saturday, November 10,
2018, 1:00 p.m. ET |
Location: |
Room 204ABC, Walter E.
Washington Convention Center |
|
|
P351 |
ADU-S100
(MIW815) Synergizes with Checkpoint Inhibition to Elicit
an |
|
Anti-Tumor CD8+
T Cell Response to Control Distal Tumors |
|
|
P516 |
SIRPα blockade
increases the activity of multiple myeloid lineage
cells, |
|
enhances
dendritic cell cross-presentation, and aids in remodeling
the |
|
tumor
microenvironment |
Session: |
Concurrent Session 104:
Immune Checkpoints – Beyond PD-1 |
Date/Time: |
Friday, November 9,
2018, 4:30 p.m. ET |
Location: |
Hall D, Walter E.
Washington Convention Center |
|
|
P517 |
Pan-allele
anti-SIRPα antibodies that block the SIRPα–CD47
innate |
|
immune
checkpoint |
To view these abstracts, please visit the SITC website located
at https://www.sitcancer.org/2018/abstracts/general.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that are intended to transform the
treatment of challenging diseases. Aduro’s technologies, which are
designed to harness the body’s natural immune system, are being
investigated in cancer indications, autoimmune diseases and have
the potential to expand into infectious diseases. Aduro’s STING
pathway activator technology is designed to activate the STING
receptor in immune cells, which may result in a potent
tumor-specific immune response. ADU-S100 (MIW815) is the first
STING compound to enter the clinic and is currently being evaluated
in a Phase 1 clinical trial as a single agent and in combination
with ipilimumab and in a Phase 1b combination trial with
spartalizumab (PDR001), an investigational anti-PD1 immune
checkpoint inhibitor. Aduro’s B-select monoclonal antibody
technology, including BION-1301, an anti-APRIL antibody, is
comprised of a number of immune modulating assets in research and
development. Aduro is collaborating with leading global
pharmaceutical companies to expand its products and technologies.
For more information, please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
regarding our intentions or current expectations concerning, among
other things, the potential for ADU-S100 alone or in combination,
preliminary observations from early dose cohorts in the Phase 1b
trial of ADU-S100 in combination with spartalizumab, the timing of
clinical data, our and Novartis’ commitment to continue to explore
ADU-S100 as a combination agent and our ability to advance our drug
development programs on our own or with our collaborators. In some
cases you can identify these statements by forward-looking words
such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,”
“project,” “expect” or the negative or plural of these words or
similar expressions. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including, but not limited to,
early or preliminary clinical trial results may not be predictive
of future results, our history of net operating losses and
uncertainty regarding our ability to achieve profitability, our
ability to develop and commercialize our product candidates, our
ability to use and expand our technologies to build a pipeline of
product candidates, our ability to obtain and maintain regulatory
approval of our product candidates, our ability to operate in a
competitive industry and compete successfully against competitors
that have greater resources than we do, our reliance on third
parties, and our ability to obtain and adequately protect
intellectual property rights for our product
candidates. We discuss many of these risks in greater
detail under the heading “Risk Factors” contained in our quarterly
report on Form 10-Q for the quarter ended September 30, 2018, which
is on file with the Securities and Exchange Commission. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Contact: |
|
Media Contact: |
Noopur Liffick |
|
Aljanae Reynolds |
Investor Relations & Corporate Affairs |
|
510-809-2452 |
510-809-2465 |
|
press@aduro.com |
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024